168 related articles for article (PubMed ID: 37339995)
21. BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.
Uçkun E; Siaw JT; Guan J; Anthonydhason V; Fuchs J; Wolfstetter G; Hallberg B; Palmer RH
J Mol Biol; 2021 Sep; 433(19):167158. PubMed ID: 34273398
[TBL] [Abstract][Full Text] [Related]
22. Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells.
Jost T; Schultz AK; Frey B; Vu J; Fietkau R; Distel LV; Hecht M
Neoplasia; 2022 May; 27():100780. PubMed ID: 35278911
[TBL] [Abstract][Full Text] [Related]
23. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
25. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
[TBL] [Abstract][Full Text] [Related]
26. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
[TBL] [Abstract][Full Text] [Related]
27. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
[TBL] [Abstract][Full Text] [Related]
29. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells.
Wang L; Xu X; Liu T; Wang J; Shen J; Guo M; Wu Y; Zhai X; Zuo D
J Pharm Pharmacol; 2020 Oct; 72(10):1370-1382. PubMed ID: 32596809
[TBL] [Abstract][Full Text] [Related]
30. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
31. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
[TBL] [Abstract][Full Text] [Related]
32. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
Sun K; Nie L; Nong L; Cheng Y
Thorac Cancer; 2021 Jun; 12(12):1927-1930. PubMed ID: 33960639
[TBL] [Abstract][Full Text] [Related]
33. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.
Tsuji T; Ozasa H; Aoki W; Aburaya S; Yamamoto Funazo T; Furugaki K; Yoshimura Y; Yamazoe M; Ajimizu H; Yasuda Y; Nomizo T; Yoshida H; Sakamori Y; Wake H; Ueda M; Kim YH; Hirai T
Nat Commun; 2020 Jan; 11(1):74. PubMed ID: 31900393
[TBL] [Abstract][Full Text] [Related]
34. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
35. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
[TBL] [Abstract][Full Text] [Related]
36. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Dagogo-Jack I; Yoda S; Lennerz JK; Langenbucher A; Lin JJ; Rooney MM; Prutisto-Chang K; Oh A; Adams NA; Yeap BY; Chin E; Do A; Marble HD; Stevens SE; Digumarthy SR; Saxena A; Nagy RJ; Benes CH; Azzoli CG; Lawrence MS; Gainor JF; Shaw AT; Hata AN
Clin Cancer Res; 2020 Jun; 26(11):2535-2545. PubMed ID: 32086345
[TBL] [Abstract][Full Text] [Related]
37. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
Funazo T; Tsuji T; Ozasa H; Furugaki K; Yoshimura Y; Oguri T; Ajimizu H; Yasuda Y; Nomizo T; Sakamori Y; Yoshida H; Kim YH; Hirai T
Mol Cancer Ther; 2020 Jun; 19(6):1320-1327. PubMed ID: 32217741
[TBL] [Abstract][Full Text] [Related]
38. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
[TBL] [Abstract][Full Text] [Related]
39. Hexokinases II-mediated glycolysis governs susceptibility to crizotinib in ALK-positive non-small cell lung cancer.
Lin C; Chen H; Han R; Li L; Lu C; Hao S; Wang Y; He Y
Thorac Cancer; 2021 Dec; 12(23):3184-3193. PubMed ID: 34729938
[TBL] [Abstract][Full Text] [Related]
40. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]